Abstract
Introduction
Tramadol, as a centrally-acting, opioid-like analgesic with serotonin reuptake inhibition property, is one of the most prescribed analgesics in the world. We assessed the incidence of seizure, as it is one of the most important adverse effects.
Methods
In a cross-sectional study, 215 cases of tramadol users or abusers who were admitted to Loghman-Hakim Hospital Poisoning Center (LHHPC) in Tehran during a 5-month period, from April 2007 to September 2007, were assessed to evaluate the occurrence of seizure. Patients with positive history of co-ingestion of other drugs, addiction, convulsive disorders, renal diseases, or head trauma with abnormal electroencephalography (EEG) or computerized tomography (CT) scan of the brain were excluded, thus 132 patients were included in the study. For patients who had seizure, CT scan of the brain and EEG were performed, and frequency and type of seizure were identified. Mean tramadol dose was compared between patients with and without seizure.
Results
Among the patients, 97 (73.5%) were male. Seizure occurred in 61 patients (46.2%) within 24 hours after tramadol ingestion. The majority of patients who had seizure were male (male, 83.6% vs. female, 16.4%). Mean tramadol dose was lower among females than males (males, 2413 mg vs. females, 1706 mg), but the difference was not statistically significant. Of 35 patients with documented seizure type, all showed generalized tonic-clonic seizure and 12 patients had abnormal EEG (35.3%). No statistically significant difference was observed in mean tramadol intake between patients with or without seizure. Analysis of patients with seizure, according to tramadol intake, indicated that most patients used tramadol in the dose range of 500–1000 mg followed in occurrence by 1500–2000 mg, then 100–500 mg, 2500–3000 mg, and 3500–4000 mg.
Conclusions
Mean tramadol intake does not differ between patients with and without seizure, and the most common dose range in those with seizure is 500–1000 mg. We thus conclude that the incidence of seizure with tramadol is not dose dependent.
Article PDF
Similar content being viewed by others
References
Frink MC, Hennies HH, Englberger W, et al. Influence of tramadol on neurotransmitter systems of the rat brain.Arzneimittelforschung 1996;46:1029–1036.
Lai J, Ma SW, Porreca F, et al. Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells.Eur J Pharmacol 1996;316:369–372.
Nikfar S, Kebriaeezadeh A, Majdzadeh R, Abdollahi M. Monitoring of National Drug Policy (NDP) and its standardized indicators: conformity to decisions of the national drug selecting committee in Iran.BMC Int Health Hum Rights 2005;5:5.
De Decker K, Cordonnier J, Jacobs W, et al. Fatal intoxication due to tramadol alone; case report and review of the literature.Forensic Sci Int 2008;175(1):79–82.
Preston KL, Jasinski DR, Testa M. Abuse potential and pharmacological comparison of tramadol and morphine.Drug Alcohol Depend 1991;27:7–17.
Cami J, Lamas X, Farre M. Acute effects of tramadol in methadone-maintained volunteers.Drugs 1994;47:39–43.
Knisely JS, Campbell ED, Dawson KS, et al. Tramadol postmarketing surveillance in health care professionals.Drug Alcohol Depend 2002;68:15–22.
Klotz U. Tramadol—the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain.Arzneimittelforschung 2003;53:681–687.
Richter W, Barth H, Flohé L, et al. Clinical investigation on the development of dependence during oral therapy with tramadol.Arzneimittelforschung 1985;35:1742–1744.
Shipton EA. Tramadol—present and future.Anaesth Intensive Care 2000;28:363–374.
Grond S, Sablotzki A. Clinical pharmacology of tramadol.Clin Pharmacokinet 2004;43:879–923.
McDiarmid T, Mackler L, Schneider DM. Clinical inquiries. What is the addiction risk associated with tramadol?J Fam Pract 2005;54:72–73.
Clarot F, Goulle JP, Vaz E, et al. Fatal overdoses of tramadol: is benzodiazepine a risk factor of lethality?Forensic Sci Int 2003;134:57–61.
Marquardt KA, Alsop JA, Albertson TE. Tramadol exposures reported to statewide poison control system.Ann Pharmacother 2005;39:1039–1044.
Jovanović-Cupić V, Martinovic Z, Nesic N. Seizures associated with intoxication and abuse of tramadol.Clin Toxicol (Phila) 2006;44:143–146.
Abdollahi M, Jalali N, Sabzevari O, et al. A retrospective study of poisoning in Tehran.J Toxicol/Clin Toxicol 1997;35(4): 387–393.
Shadnia S, Esmaily H, Sasanian G, et al. Pattern of acute poisoning in Tehran-Iran in 2003.Hum Exp Toxicol 2007;26: 753–756.
Moghadamnia AA, Abdollahi M. An epidemiological study of acute poisonings in northern Islamic Republic of Iran.East Mediterr Health J 2002;8(1):88–94.
Kahn LH, Alderfer RJ, Graham DJ. Seizures reported with tramadol.JAMA 1997;278:1661.
Spiller HA, Gorman SE, Villalobos D, et al. Prospective multicenter evaluation of tramadol exposure.J Toxicol/Clin Toxicol 1997;35:361–364.
Ultram, Ortho-McNeil Pharmaceuticals. Physician’s Desk Reference. 53rd ed. Montvale, NJ: Medical Economics, 1999, pp. 2254–2257.
Gholami K, Shalviri G, Zarbakhsh A, et al. New guideline for tramadol usage following adverse drug reactions reported to the Iranian Pharmacovigilance Center.Pharmacoepidemiol Drug Saf 2007;16:229–237.
Gardner JS, Blough D, Drinkard CR, Shatin D, et al. Tramadol and seizures: a surveillance study in a managed care population.Pharmacotherapy 2000;20:1423–1431.
Gasse C, Derby L, Vasilakis-Scaramozza C, Jick H. Incidence of first-time idiopathic seizures in users of tramadol.Pharmacotherapy 2000;20:629–634.
Jick H, Derby LE, Vasilakis C, et al. The risk of seizures associated with tramadol.Pharmacotherapy 1998;18: 607–611.
Labate A, Newton MR, Vernon GM, et al. Tramadol and new-onset seizures.Med J Aust 2005;182:42–43.
Manocha A, Sharma KK, Mediratta PK. Tramadol, a centrally acting opioid: anticonvulsant effect against maximal electroshock seizure in mice.Indian J Physiol Pharmacol 1998;42:407–411.
Shadnia S, Soltaninejad K, Heydaril K, et al. Tramadol intoxication: a review of 114 cases.Hum Exp Toxicol 2008;27: 201–205.
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was supported by a grant from Toxicological Research Center of Shaheed Beheshti University of Medical Sciences and Iranian National Center for Addiction Study of Tehran University of Medical Sciences.